公司概况 - Forte Biosciences, Inc. 是一家生物制药公司，主要研发产品候选药物FB-102，用于治疗自身免疫性疾病[40] 财务状况 - 公司截至2023年3月31日拥有大约3,590万美元的现金及现金等价物[41] - 研发费用在2023年3月31日的三个月内达到478.7万美元，较2022年同期的69.3万美元增长[50] - 公司在2023年第一季度的经营活动中，主要是因为净损失为6.8百万美元，非现金股权补偿为0.9百万美元和净营运资产减少为0.7百万美元而导致的运营活动现金流出为520.4万美元[58] 市值限制 - 公司目前的市值限制为非关联方持有的普通股市值不超过7500万美元，已达到此限制[54] 资本需求 - 公司未来资本需求主要取决于多个因素，包括产品候选品的临床试验进展、战略联盟、专利申请和生产成本等[56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-1243872 (State or other jurisdic ...

Forte Biosciences, Inc. (NASDAQ:FBRX) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Paul Wagner - CEO Dan Birch - CMO Tony Riley - CFO Conference Call Participants Mohit Bansal - Citigroup Kumar Raja - Brookline Capital Markets Michael Higgins - Ladenburg Thalmann Kalpit Patel - B. Riley Operator Welcome to Forte Biosciences First Quarter 2021 Conference Call. My name is David and I will be the operator for this call. On the call are Paul Wagner, Chairman and Chief Executive ...

Tocagen Inc. (TOCA) Tocagen and Forte Biosciences Announce Merger Conference Call February 20, 2020 8:30 AM ET Company Participants Marty Duvall - Chief Executive Officer, Tocagen Paul Wagner - Chief Executive Officer, Forte Operator Ladies and gentlemen, thank you for standing by and welcome to the Tocagen Forte Biosciences joint conference call. At this time all participant lines are in a listen only mode. Please be advised today's conference is being recorded. [Operator Instructions]. Turning to Slide 2 ...

Tocagen® No One Should Die Of CancerTM A Cancer-Selective Gene Therapy Company Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking state ...

Tocagen® No One Should Die Of CancerTM A Cancer-Selective Gene Therapy Company Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking state ...